Difference between revisions of "Fibroblast growth factor receptors"
Jump to navigation
Jump to search
(create) |
|||
| (5 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
'''Fibroblast growth factor receptor''', abbreviated '''FGFR''', a molecule that transmit growth signals for fibroblasts. | '''Fibroblast growth factor receptor''', abbreviated '''FGFR''', a molecule that transmit growth signals for fibroblasts. | ||
''FGFR2'' and ''FGFR3'' redirect here. | |||
An anti-FGFR therapy exists (''erdafitinib'').<ref>{{cite journal |vauthors=Sheth H, Limaye S, Kumar P, Shreenivas A |title=Sustained response on sequential anti-FGFR therapy in metastatic gall bladder cancer: a case report and literature review |journal=J Cancer Res Clin Oncol |volume=149 |issue=8 |pages=4915–4923 |date=July 2023 |pmid=36307559 |doi=10.1007/s00432-022-04428-w |url=}}</ref><ref>{{cite journal |vauthors=Al-Obaidy KI, Cheng L |title=Fibroblast growth factor receptor (FGFR) gene: pathogenesis and treatment implications in urothelial carcinoma of the bladder |journal=J Clin Pathol |volume=74 |issue=8 |pages=491–495 |date=August 2021 |pmid=33731335 |doi=10.1136/jclinpath-2020-207115 |url=}}</ref> | An anti-FGFR therapy exists (''erdafitinib'').<ref>{{cite journal |vauthors=Sheth H, Limaye S, Kumar P, Shreenivas A |title=Sustained response on sequential anti-FGFR therapy in metastatic gall bladder cancer: a case report and literature review |journal=J Cancer Res Clin Oncol |volume=149 |issue=8 |pages=4915–4923 |date=July 2023 |pmid=36307559 |doi=10.1007/s00432-022-04428-w |url=}}</ref><ref name=pmid33731335>{{cite journal |vauthors=Al-Obaidy KI, Cheng L |title=Fibroblast growth factor receptor (FGFR) gene: pathogenesis and treatment implications in urothelial carcinoma of the bladder |journal=J Clin Pathol |volume=74 |issue=8 |pages=491–495 |date=August 2021 |pmid=33731335 |doi=10.1136/jclinpath-2020-207115 |url=}}</ref> | ||
==Anti-FGFR therapy== | |||
It is used in: | |||
*[[Urothelial carcinoma]].<ref name=pmid33731335/> | |||
*Hepatobiliary cancers.{{fact}} | |||
==See also== | |||
*[[Classification of urothelial carcinoma by immunohistochemistry]]. | |||
==References== | ==References== | ||
{{Reflist|1}} | {{Reflist|1}} | ||
[[Category:Molecular | [[Category:Molecular pathology]] | ||
Latest revision as of 16:23, 8 March 2024
Fibroblast growth factor receptor, abbreviated FGFR, a molecule that transmit growth signals for fibroblasts. FGFR2 and FGFR3 redirect here.
An anti-FGFR therapy exists (erdafitinib).[1][2]
Anti-FGFR therapy
It is used in:
- Urothelial carcinoma.[2]
- Hepatobiliary cancers.[citation needed]
See also
References
- ↑ "Sustained response on sequential anti-FGFR therapy in metastatic gall bladder cancer: a case report and literature review". J Cancer Res Clin Oncol 149 (8): 4915–4923. July 2023. doi:10.1007/s00432-022-04428-w. PMID 36307559.
- ↑ 2.0 2.1 "Fibroblast growth factor receptor (FGFR) gene: pathogenesis and treatment implications in urothelial carcinoma of the bladder". J Clin Pathol 74 (8): 491–495. August 2021. doi:10.1136/jclinpath-2020-207115. PMID 33731335.